Special Issue

Pharmacogenomics and Personalized Treatment

Message from the Guest Editors

The Special Issue titled "Pharmacogenomics and Personalized Treatment" investigates the rapidly growing field of pharmacogenomics, focusing on how genetic variations affect drug efficacy and toxicity, with significant implications for the development of personalized treatment strategies. This Special Issue will emphasize key research areas, including gene-drug interactions, pharmacogenomic biomarkers, ethical, legal, and social implications, and AI and machine learning in pharmacogenomics, to facilitate the integration of genetic data into clinical practice, leading to more effective, safe, and individualized treatments for patients. The aim of this issue is to stimulate discussion on the integration of pharmacogenomic data into routine clinical practice while addressing the challenges associated with their implementation. We encourage submissions that explore innovative methodologies, case studies, and those examining the future of pharmacogenomics in the modeling of personalized healthcare settings.

Guest Editors

Dr. Livija Šimičević

1. Department of Medical Chemistry, Biochemistry and Clinical Chemistry, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
2. Division for Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, 10000 Zagreb, Croatia

Dr. Lana Ganoci

Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, 10000 Zagreb, Croatia

Deadline for manuscript submissions

10 November 2025

GCAT
TACG
GCAT

Genes

**an Open Access Journal
by MDPI**

**Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed**

MDPI

About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:
JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))